Drug Profile

FLAG 003

Alternative Names: FLAG-003

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Duquesne University
Developer FLAG Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Glioma
New Molecular Entity Yes

Highest Development Phases

Preclinical Diffuse intrinsic pontine glioma
No development reported Glioblastoma

Most Recent Events

28 May 2025 No recent reports of development identified for preclinical development in Glioblastoma in USA (PO)
16 Jul 2024 Preclinical trials in Diffuse intrinsic pontine glioma in USA (PO)
16 Jul 2024 FLAG Therapeutics announces intention to submit IND application to US FDA for Diffuse intrinsic pontine glioma in the fourth quarter of 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com